<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363295</url>
  </required_header>
  <id_info>
    <org_study_id>002</org_study_id>
    <nct_id>NCT03363295</nct_id>
  </id_info>
  <brief_title>Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis</brief_title>
  <official_title>Evaluation and Comparison of Macular and Choroidal Thickness After Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Pernambuco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal de Pernambuco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the macular and choroidal thickness of patients&#xD;
      submitted to intracameral moxifloxacin during the phacoemulsification surgery for&#xD;
      endophthalmitis prophylaxis.&#xD;
&#xD;
      The investigators propose a randomized clinical trial double-blind. The patients will be&#xD;
      divided into two groups: one will receive intracameral moxifloxacin injection during&#xD;
      phacoemulsification surgery and the other won't.&#xD;
&#xD;
      Both Spectral Domain - Optical Coherence Tomography (SD-OCT) and Enhanced Depth Imaging -&#xD;
      Optical Coherence Tomography (EDI-OCT) will be performed for each patient pre-operatively and&#xD;
      on the 30th and 60th postoperative days.&#xD;
&#xD;
      After collecting, the data will be compared to evaluate if there was any difference in the&#xD;
      macular thickness and choroidal thickness between the two groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title:&#xD;
&#xD;
      Evaluation and Comparison of Macular and Choroidal Thickness after Intracameral Moxifloxacin&#xD;
      for Prevention of Postcataract Endophthalmitis&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      The objective of this study is to evaluate if the using of intracameral moxifloxacin cause&#xD;
      changes in macular and choroidal thickness.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      A randomized clinical trial will be conducted in the Hospital of Clinics at State University&#xD;
      of Campinas (UNICAMP). The patients that will be submitted to phacoemulsification surgery&#xD;
      will be divided into two groups. The first group will receive 0,03ml intracameral&#xD;
      moxifloxacin after phacoemulsification surgery, while the second group won't receive any&#xD;
      antibiotics intracamerally. Both groups will apply eyedrops as usual in the postoperative.&#xD;
&#xD;
      The investigators will evaluate those patients blindly. Each patient will be examined using&#xD;
      Spectral Domain - Optical Coherence Tomography (SD-OCT) and Enhanced Depth Imaging - Optical&#xD;
      Coherence Tomography (EDI-OCT), in the pre-operative, at the 30th postoperative and at the&#xD;
      60th postoperative. The data will be collected regarding macular central thickness and&#xD;
      choroidal thickness.&#xD;
&#xD;
      The exclusion criteria will be:&#xD;
&#xD;
        -  Patients who had any macular changes prior to the surgery (including epiretinal&#xD;
           membrane, macular edema, drusen or any other)&#xD;
&#xD;
        -  diabetic patients&#xD;
&#xD;
        -  patients who had any complications during the cataract surgery&#xD;
&#xD;
        -  patients who refuse to participate in the trial, or refuse to sign the consent form&#xD;
&#xD;
      After collecting data, the two groups will be compared regarding changes in macular thickness&#xD;
      and choroidal thickness from the pre-operative, the 30th and the 60th postoperative.&#xD;
&#xD;
      The investigators expect that there will be no statistical difference between groups&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Both the patients and the investigator will be masked. The cataract surgeon won't be.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Macular Thickness</measure>
    <time_frame>Change from baseline, 30th day postoperative and 60th day postoperative</time_frame>
    <description>Comparison of change in macular thickness using Spectral Domain - Optical Coherence Tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Choroidal Thickness</measure>
    <time_frame>Change from baseline, 30th day postoperative and 60th day postoperative</time_frame>
    <description>Comparison of change in macular thickness using Enhanced Depth Imaging - Optical Coherence Tomography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Endophthalmitis</condition>
  <condition>Macula Edema</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Intracameral moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 0,03ml of moxifloxacin in the anterior chamber following phacoemulsification surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No - Intracameral moxifloxacin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group won't receive any prophylaxis after phacoemulsification surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Injection</intervention_name>
    <description>One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery</description>
    <arm_group_label>Intracameral moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patients that will be submitted to phacoemulsification surgery in the Hospital de&#xD;
             Clinicas of State University of Campinas (BRAZIL)&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
          -  Patients who are able to perform SD-OCT&#xD;
&#xD;
          -  Patients who sign the consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients&#xD;
&#xD;
          -  Patients with any macular changes prior to the surgery (epiretinal membranes, age&#xD;
             macular disease, macular edema...)&#xD;
&#xD;
          -  Patients who had any complication during phacoemulsification surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital das Clínicas da UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083888</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 25, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>May 2, 2021</last_update_submitted>
  <last_update_submitted_qc>May 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal de Pernambuco</investigator_affiliation>
    <investigator_full_name>Rodrigo Pessoa Cavalcanti Lira</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>endophthalmitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endophthalmitis</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

